Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Insulin aspart (NovoRapid®)
Insulin aspart · 14 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Insulin therapy | EXPERIMENTAL | Insulin Aspart, Biphasic Insulin Aspart 70 and 50 \& Fast-acting Human Insulin |
| Insulin aspart and neutral protamine Hagedorn insulin | EXPERIMENTAL | - |
| insulin aspart | EXPERIMENTAL | - |
| human insulin | ACTIVE_COMPARATOR | - |
| 3 mm needle | EXPERIMENTAL | - |
| 3.5 mm needle | EXPERIMENTAL | - |
| 4 mm needle | ACTIVE_COMPARATOR | - |
| Treatment sequence 1 - IM treatment group | EXPERIMENTAL | - |
| Treatment sequence 2 - IM treatment group | EXPERIMENTAL | - |
| Treatment sequence 1 - IV treatment group | EXPERIMENTAL | - |
| Treatment sequence 2 - IV treatment group | EXPERIMENTAL | - |
| Insulin aspart 100U/mL | ACTIVE_COMPARATOR | - |
| Insulin aspart 200U/mL | EXPERIMENTAL | - |
| U200 | EXPERIMENTAL | - |
| U100 | ACTIVE_COMPARATOR | - |
| NN2000 | EXPERIMENTAL | - |
| IAsp | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin | DRUG | 0.2 U/IU/kg subcutaneous injection, single dose |
| insulin lispro | DRUG | - |
| insulin aspart | DRUG | - |
| inhaled human insulin | DRUG | - |
| insulin NPH | DRUG | - |
| human soluble insulin | DRUG | Injected subcutaneously (s.c, under the skin) as meal time insulin |
| insulin human | DRUG | At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods. |
| pump | DEVICE | - |
| insulin glargine | DRUG | - |
Inclusion Criteria: * Informed consent obtained before any trial-related activities. * Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one year of diagnosis. * Insulin treatment of any regime for more than one year at time of inclusion. * Total insulin demand ≥ 0,4 U/...
Insulin aspart is used to treat diabetes, including type 1 diabetes mellitus. It is a rapid-acting insulin analog given to lower blood glucose. The clinical program covers both type 1 diabetes and broader diabetes populations, with trials enrolling adults aged 18 years and older.
Insulin aspart works as an agonist at INSR, the insulin receptor. By binding and activating this receptor, it triggers the signaling that drives glucose uptake into cells and lowers blood glucose, mimicking the action of endogenous human insulin.
Insulin aspart is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor behind the clinical trial program for the asset across its diabetes indications.
Insulin aspart is in Phase 3 development. Its trial record includes 13 studies, all of which are completed, with no active trials listed. The completed studies span Phase 1 pharmacokinetic and bioequivalence work through Phase 3 safety and efficacy testing.
Insulin aspart has been studied in completed trials including NCT01707134, a Phase 3 safety and efficacy study in type 1 diabetes with 753 participants, and NCT02594033, a Phase 1 pharmacokinetic needle-feature study. Phase 1 bioequivalence and formulation comparison trials include NCT01530048 and NCT01698697.
Insulin aspart is also known as NovoRapid, and it is referenced under names including BIAsp 70, BIAsp50, and human insulin. These alternative names all point to the same insulin aspart asset developed by Novo Nordisk.